News

Sovereign Capability at Scale

A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis.

Health Security Systems Australia (HSSA) is engaging with leading scientific experts from across Australia, led by Griffith University, including the Australian Rickettsial Reference Laboratory in Geelong, the NSW Department of Primary Industries, the University of Western Australia, and industry partner BioCina Pty Ltd, an Australian-based global biologics Contract Development Manufacturing Organisation (CDMO). (more…)

Pushing back against viruses with pandemic potential

Health Security Systems Australia (HSSA) is working with experts at the University of Melbourne at the Peter Doherty Institute for Infection and Immunity (Doherty Institute), The University of Queensland’s National Biologics Facility, and industry partner Biointelect Pty Ltd to develop a novel therapeutic platform technology to combat multiple viral pathogens with pandemic potential. (more…)

SABRE Alliance launched to align and leverage Australia’s biotech strengths

Defence launched the ‘Safeguarding Australia through Biotechnology Response and Engagement’ (SABRE) Alliance in July 2022. SABRE seeks to bring together biotech capabilities from Australia’s universities, research institutes, SMEs and manufacturers to work together to meet the needs of the Defence and national security sectors. (more…)

New project to build local capability for global impact

Health Security Systems Australia (HSSA) has engaged with ZiP Diagnostics, Axxin and Defence scientists to advance a point-of-care (POC) diagnostic capability for the detection of priority pathogens in the Indo-Pacific region. (more…)